<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30052095</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>10</Month>            <Day>19</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>19</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1744-8379</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>18</Volume>                    <Issue>6</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Dec</Month>                    </PubDate>                </JournalIssue>                <Title>Expert review of pharmacoeconomics &amp; outcomes research</Title>                <ISOAbbreviation>Expert Rev Pharmacoecon Outcomes Res</ISOAbbreviation>            </Journal>            <ArticleTitle>Health economic impact of liquid biopsies in cancer management.</ArticleTitle>            <Pagination>                <MedlinePgn>593-599</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1080/14737167.2018.1505505</ELocationID>            <Abstract>                <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Liquid biopsies (LBs) are referred to as the sampling and analysis of non-solid tissue, primarily blood, as a diagnostic and monitoring tool for cancer. Because LBs are largely non-invasive, they are a less-costly alternative for serial analysis of tumor progression and heterogeneity to facilitate clinical management. Although a variety of tumor markers are proposed (e.g., free-circulating DNA), the clinical evidence for Circulating Tumor Cells (CTCs) is currently the most developed. Areas covered: This paper presents a health economic perspective of LBs in cancer management. We first briefly introduce the requirements in biomarker development and validation, illustrated for CTCs. Second, we discuss the state-of-art on the clinical utility of LBs in breast cancer in more detail. We conclude with a future perspective on the clinical use and reimbursement of LBs Expert commentary: A significant increase in clinical research on LBs can be observed and the results suggest a rapid change of cancer management. In addition to studies evaluating clinical utility of LBs, a smooth translation into clinical practice requires systematic assessment of the health economic benefits. This paper argues that (early stage) health economic research is required to facilitate its clinical use and to prioritize further evidence development.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>IJzerman</LastName>                    <ForeName>Maarten J</ForeName>                    <Initials>MJ</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0001-5788-5805</Identifier>                    <AffiliationInfo>                        <Affiliation>a Department of Health Technology and Services Research , University of Twente , Enschede , the Netherlands.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>b University of Melbourne, Faculty of Medicine, Dentistry and Health Sciences , Victorian Comprehensive Cancer Centre and Centre for Cancer Research , Melbourne , Australia.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>c Luxembourg Institute of Health, Dept. Health Economics and Evidence Synthesis , Luxembourg.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Berghuis</LastName>                    <ForeName>A M Sofie</ForeName>                    <Initials>AMS</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0001-6306-2936</Identifier>                    <AffiliationInfo>                        <Affiliation>a Department of Health Technology and Services Research , University of Twente , Enschede , the Netherlands.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>de Bono</LastName>                    <ForeName>Johann S</ForeName>                    <Initials>JS</Initials>                    <AffiliationInfo>                        <Affiliation>d Royal Marsden Hospital, Institute for Cancer Research , Clinical studies department , Surrey , UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Terstappen</LastName>                    <ForeName>Leon W M M</ForeName>                    <Initials>LWMM</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0001-5944-3787</Identifier>                    <AffiliationInfo>                        <Affiliation>e Department of Medical Cell Biophysics , University of Twente , Enschede , the Netherlands.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>07</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Expert Rev Pharmacoecon Outcomes Res</MedlineTA>            <NlmUniqueID>101132257</NlmUniqueID>            <ISSNLinking>1473-7167</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>                <QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000073890" MajorTopicYN="N">Liquid Biopsy</DescriptorName>                <QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName>                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>                <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>                <QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D009360" MajorTopicYN="N">Neoplastic Cells, Circulating</DescriptorName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D012051" MajorTopicYN="N">Reimbursement Mechanisms</DescriptorName>                <QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Liquid biopsies</Keyword>            <Keyword MajorTopicYN="N">biomarker</Keyword>            <Keyword MajorTopicYN="N">cancer</Keyword>            <Keyword MajorTopicYN="N">circulating tumor cells</Keyword>            <Keyword MajorTopicYN="N">ctDNA</Keyword>            <Keyword MajorTopicYN="N">diagnostic</Keyword>            <Keyword MajorTopicYN="N">health economics</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>7</Month>                <Day>28</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>20</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>7</Month>                <Day>28</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30052095</ArticleId>            <ArticleId IdType="doi">10.1080/14737167.2018.1505505</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>